Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Set & Setting

Psilocybin for Set & Setting

54 papers and 36 clinical trials exploring psilocybin as a treatment for set & setting.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationApproximately 264 million individuals worldwide suffer from depression, with many seeking innovative treatment options such as psychedelic-assisted therapy.

Set & Setting

The concept of 'set and setting' is critical in psychedelic research, influencing therapeutic outcomes in clinical environments. Creating optimal conditions is essential for maximising the efficacy and safety of psychedelic-assisted therapies, particularly in the context of mental health disorders.

Full Set & Setting profile

Academic Research

54 papers
Open Accessindividual

Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study

In a retrospective case series (n=19) of treatment‑resistant depression patients treated with psilocybin (20–35 mg) in routine clinical practice, depressive symptoms decreased significantly with large effect sizes on MADRS and BDI, though response and remission rates were lower than in controlled trials and no additive benefit of multiple doses was found.

Published
June 1, 2026
Journal
The Lancet Regional Health – Europe
Authors
Jungwirth, J., Westenhöfer, S., Aicher, H., Provaznikova, B., Kronenberg, G., Seifritz, E., Prinz, S., Olbrich, S.
Open Accessindividual

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis

Qualitative interviews with 12 participants from a randomized, placebo‑controlled single‑dose psilocybin trial for treatment‑refractory OCD showed that set and setting strongly shaped acute (often partial) perceptual, emotional and metacognitive experiences, which were followed by post‑dosing changes in OCD symptoms, perceptions and behavioural/metacognitive processes. These changes mapped onto putative mechanisms of ERP and ACT, suggesting hypotheses for further study and potential value in integrating psilocybin with structured psychotherapy for OCD.

Published
December 10, 2025
Journal
Frontiers in Psychiatry
Authors
Ching, T. H. W., Stahnke, B., Shnayder, S., Agin-Liebes, G., Adams, T. G., Amoroso, L., Baiz, O., Belser, A., Bohner, C., Burke, M., D’Amico, E., DePalmer, G., Eilbott, J., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., Purohit, P., Schaer, H., Sierra, Y. P., Witherow, C., Pittenger, C., Kelmendi, B.
Paywallindividual

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis

In a retrospective analysis of 233 participants with treatment‑resistant depression given 1, 10 or 25 mg COMP360 psilocybin, dose was the strongest and most consistent predictor of the acute psychedelic experience, while pretreatment clinical characteristics made only modest, variable contributions (positive affect, lower generalized anxiety, higher executive function and greater personality‑disorder symptoms each influenced different experience dimensions). These results challenge the assumption that pretreatment traits are major determinants of the subjective psilocybin experience.

Published
December 9, 2025
Journal
Journal of Clinical Psychopharmacology
Authors
Kirlić, N., Atli, M., Mistry, S., Gold, M., Goodwin, G. M.
Open Accessindividual

Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression

This qualitative study (n=28 interviews) of participants in a psilocybin-assisted therapy trial for cancer-related depression found that therapeutic benefits were closely tied to participants' ability to surrender (accepting and remaining open to the experience's intensity and unpredictability), with a safe, supportive, and ethical environment critical to fostering trust and engagement, and preparation and integration key to maximizing benefit, whilst music played a significant but variable role and ceremonial elements added meaning for many despite the clinical setting providing safety.

Published
November 1, 2025
Journal
General Hospital Psychiatry
Authors
Beaussant, Y., Tarbi, E., Nigam, K. B., Miner, S., Sager, Z., Sanders, J. J., Ljuslin, M., Guérin, B., Sholevar, R., Roddy, K., Tulsky, J., Agrawal, M.
Open Accessindividual

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

This prospective, longitudinal study (n=679) examined the effects of psilocybin use on emotional experiences, particularly feelings of shame and guilt. The study found that while most participants had positive experiences with psilocybin, acute feelings of shame or guilt were common (68%), and the ability to work through these feelings positively correlated with well-being in the weeks following use. On average, psilocybin resulted in a small but significant decrease in trait shame, which was maintained for 2-3 months after use, though in a minority of participants (30%), trait shame increased.

Published
February 7, 2025
Journal
Journal of Psychedelic Drugs
Authors
Mathai, D. S., Roberts, D. E., Nayak, S. M., Sepeda, N. D., Lehrner, A., Johnson, M. W., Lowe, M. X., Jackson, H., Garcia-Romeu, A.
Paywallindividual

Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy

This technical report (2024) describes the evolving guidelines for facilitator use of touch in a group retreat-based format of psilocybin-assisted therapy. The primary goal is to create a safe and supportive haptic experience during sessions, with a secondary goal of maintaining therapeutic boundaries and responding to participant experiences with empathy.

Published
December 1, 2024
Journal
Psychedelic Medicine
Authors
Back, A., Myers, S., Guy, J., Perez, J., Thorn, L. L., Mcgregor, B.

Clinical Trials

36 trials
Not yet recruitingPhase II

FIFO-PAT-20: A sequential multiple assignment randomised controlled trial comparing the efficacy and safety of treatment as usual against a Fly-In-Fly-Out (FIFO) model of Psilocybin-Assisted Therapy (PAT) for Major Depressive Disorder (MDD), alongside randomised adjunctive support (virtual-reality vs journalling)

This open-label, randomised controlled Phase II trial (n=30) will test a six-week Fly-In-Fly-Out Psilocybin-Assisted Therapy (FIFO-PAT) programme for major depressive disorder (MDD), using a single 25 mg oral dose of psilocybin alongside psychotherapy and either a virtual-reality (VR) integration tool or journaling.

Started
August 4, 2025
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
ACTRN12625000799459
Not yet recruitingPhase I

A Phase 1, Open-label, Pilot Study to Assess the Safety, Feasibility and Initial Efficacy of IV infused Psilocin (TRP-8803) Administration in Concert with Psychotherapy Among Adult Patients with Binge Eating Disorder (BED)

This Phase I open-label trial (n=12) will investigate the safety, feasibility, and initial efficacy of intravenous psilocin (TRP-8803), administered in two doses (ranging from 6.7 mg to 15 mg) two weeks apart, paired with psychedelic-assisted psychotherapy for adults with binge eating disorder (BED).

Started
June 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
ACTRN12625000330448p
RecruitingPhase I

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects (MDMA-Psilo)

Double-blind, placebo-controlled, 4-period crossover study (n=24) testing 20 mg psilocybin and 100 mg MDMA alone and combined in healthy adults to assess subjective and autonomic effects.

Started
April 1, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06884514
RecruitingPhase I

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants (LPD)

This randomised, placebo-controlled, triple-blind Phase I crossover trial (n=24) will compare the acute and subacute effects of LSD (150µg), psilocybin (30mg), and DMT (up to 2 mg/min intravenous infusion) in healthy adults, with all sessions standardised using ketanserin (20 mg IV) to end the psychedelic experience after three hours.

Started
April 1, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06899334
RecruitingPhase I

Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs (DIPP-RCFT)

Randomised controlled feasibility trial (n=40) comparing a 21-day meditation-based DIPP versus a music-based DIPP control, each followed by a supervised 25 mg psilocybin session at University College London.

Started
March 1, 2025
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
NCT06815653
Active not recruitingPhase I

Psilocybin Brain Stimulation and Imaging Pilot Study (OPTE)

This open-label Phase I trial (n=15) will investigate the effects of psilocybin (25mg) on brain function and cognitive control in healthy adults, using electroencephalogram (EEG) and transcranial magnetic stimulation (TMS).

Started
March 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06835699

Explore further

Search all Psilocybin papers Search all Set & Setting trials Full Psilocybin profile Full Set & Setting profile